ACR Convergence 2022 Archives - ACR Meeting Abstracts

Abstract Number: 1837

Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology
Abstract Number: 2231

Earlier and More Aggressive Treatment of Major Organ Involvement with Biologics May Prevent Relapses or Further New Organ Involvement in Behçet’s Disease
Abstract Number: 2114

Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Abstract Number: 0779

Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab
Abstract Number: 2021

Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome
Abstract Number: 1413

Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study
Abstract Number: 1354

Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application
Abstract Number: 0356

Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
Abstract Number: 2115

Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Abstract Number: 1986

Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
Abstract Number: 1384

Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 1376

Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children
Abstract Number: 0238

Educational Experience and Engagement in the First Two Years of RheumMadness, an Online Community of Inquiry
Abstract Number: 0736

Educational Needs Among Health Professionals in Rheumatology: Low Awareness of EULAR Offerings and Unfamiliarity with Course Content as a Major Barrier – a EULAR Funded European Survey
Abstract Number: 1644

Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Metabolic Syndrome-Associated Osteoarthritis: A Randomized Controlled Trial
Abstract Number: 1998

Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
Abstract Number: 0940

Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study
Abstract Number: 1001

Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 0977

Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
Abstract Number: 0900

Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients
Abstract Number: 0407

Effect of Biologics in MRI/CRP Subgroups of Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Abstract Number: 0982

Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Abstract Number: L05

Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase
Abstract Number: 0050

Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice
Abstract Number: 0279

Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA
Abstract Number: 0863

Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study
Abstract Number: 0994

Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus
Abstract Number: 2085

Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
Abstract Number: 0719

Effect of Patient-reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
Abstract Number: 1307

Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial
Abstract Number: L15

Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study
Abstract Number: 0190

Effect of Shared Decision-making on Trust in Physician in the Clinical Practice of Systemic Lupus Erythematosus: The TRUMP2-SLE Study
Abstract Number: 1805

Effect of Short-Term Fruit Juice and Sugared Beverage Intake on Risk of Recurrent Gout Flares
Abstract Number: 0739

Effect of Tailored Self-Management Interventions on Health Outcomes in Individuals with Chronic Musculoskeletal Conditions
Abstract Number: 1106

Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia Rheumatica on Glucocorticoid Therapy: A Randomized Clinical Trial
Abstract Number: 2239

Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial
Abstract Number: 0158

Effect of Type I IFN on Mitochondria and Muscle Weakness in Myositis
Abstract Number: 2143

Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Abstract Number: 0305

Effect of Upadacitinib on Bone Erosion Repair in Rheumatoid Arthritis: A Pilot Study
Abstract Number: 0297

Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Abstract Number: 1553

Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
Abstract Number: 0301

Effectiveness and Safety of Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Third Interim Analysis of a German Non-Interventional, Prospective, Multicenter Study (ESCALATE-RA)
Abstract Number: 0699

Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 1435

Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study
Abstract Number: 0129

Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
Abstract Number: 1675

Effectiveness of Intensive Diet and Exercise on Knee Pain Among Communities with Knee Osteoarthritis, Overweight, and Obesity: The WE-CAN Pragmatic Randomized Clinical Trial
Abstract Number: 1547

Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica
Abstract Number: 1949

Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
Abstract Number: 0298

Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study
Abstract Number: 0303

Effectiveness of Upadacitinib in the Treatment of Rheumatoid Arthritis: Analysis of 6-Month Real-World Data from the United Rheumatology Normalized Integrated Community Evidence (UR-NICETM) Database
Abstract Number: 1745

Effects of Excess IL-18 in Mixed Inflammatory Environments
Abstract Number: 0921

Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile
Abstract Number: 1997

Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis
Abstract Number: 2125

Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials
Abstract Number: 1009

Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial
Abstract Number: 1072

Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Abstract Number: 1829

Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
Abstract Number: 0416

Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Abstract Number: 1656

Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial
Abstract Number: 1587

Efficacy and Safety of Curcumin in Maintaining Remission During Disease Modifying Anti Rheumatic Drug Withdrawal in Rheumatoid Arthritis at 52 Weeks: Phase III Double-Blind Randomized Placebo Controlled Trial
Abstract Number: 1117

Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 0918

Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study
Abstract Number: 0403

Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
Abstract Number: 0413

Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Abstract Number: 2145

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
Abstract Number: 0422

Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort
Abstract Number: 2031

Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Abstract Number: 0549

Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis
Abstract Number: 0405

Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Baseline BMI: A Post Hoc Analysis of Phase 2 and Phase 3 Trials
Abstract Number: 0421

Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
Abstract Number: 1107

Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study
Abstract Number: 1036

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking
Abstract Number: 0286

Efficacy and Safety of Upadacitinib in Patients Across Races with Rheumatoid Arthritis: A Post Hoc Analysis of Six Phase 3 Clinical Trials
Abstract Number: 0414

Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
Abstract Number: 0282

Efficacy and Safety of Upadacitinib in TNFi-IR Patients with Rheumatoid Arthritis from Three Phase 3 Clinical Trials
Abstract Number: 1832

Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study
Abstract Number: 0364

Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)
Abstract Number: 1035

Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
Abstract Number: 1882

Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
Abstract Number: 1876

Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)
Abstract Number: 1075

Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
Abstract Number: 1504

Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
Abstract Number: 2209

Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
Abstract Number: 1932

Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Abstract Number: 0419

Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline
Abstract Number: 2146

Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
Abstract Number: L10

Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM)
Abstract Number: 1824

eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy
Abstract Number: 0052

Elucidating Androgen Effects on Focal Erosions in TNF-Induced Inflammatory Arthritis
Abstract Number: 0626

Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
Abstract Number: 2035

Elucidating the Factors That Influence the Use of Minor Salivary Gland Biopsy for the Evaluation of Childhood Sjögren’s Disease
Abstract Number: 0119

Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions Varies by Geographic Location of Residence
Abstract Number: 2100

Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus
Abstract Number: 0185

Empowered2work: Development and Delivery of a Multi-faceted Peer-coaching Workshop Focusing on Health Promotion and Ergonomic Issues in the Workplace
Abstract Number: 1099

Empowering Patients with Lupus Through Their Photographs: Application of the Photovoice Method to Understand Social Determinants of Health
Abstract Number: 1008

Endothelial Dysfunction in Axial Spondyloarthritis and Its Association with Clinical Disease Characteristics
Abstract Number: PP17

Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis That Works to Improve My Mental Health While Living with RA
Abstract Number: 1025

Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Entheseal Tissue from Psoriatic Arthritis Patients
Abstract Number: 1508

Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
Abstract Number: 2080

Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
Abstract Number: 1593

Epidemiology and Outcomes of Infection-related Hospitalizations in Young Adults with SLE: Data from National Inpatient Sample
Abstract Number: 1773

Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
Abstract Number: 0484

Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis
Abstract Number: 1475

Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus
Abstract Number: 0695

Epidemiology of Behçet’s Disease in Northern Spain
Abstract Number: 1767

Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Abstract Number: 1638

Epidemiology of Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease in the Veterans Health Administration from 2004 to 2018
Abstract Number: 1175

Epigenetic Regulation of MicroRNA-126 in Scleroderma Is Associated with Upregulation of DNA Methyltransferase-1, Repression of Endothelial Nitric Oxide Synthase Expression, and Enhanced Platelet Adhesion to Endothelial Cells
Abstract Number: 1143

Epigenome-wide Analysis of Osteoarthritis in the Multicenter Osteoarthritis Study
Abstract Number: 1155

Epigenome-Wide Integrative Association Study on Spondyloarthritis and Psoriatic Arthritis
Abstract Number: 0120

Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
Abstract Number: 1229

Erosion Score and Erosive Joint Number Using Radiography: Clinical Implications in Patients with ACPA+ Early RA Treated with Abatacept
Abstract Number: 0113

Escalation to Biologics After Methotrexate Among US Veterans with Rheumatoid Arthritis Living in Rural versus Urban Areas
Abstract Number: 1831

Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)
Abstract Number: 2072

Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
Abstract Number: 1483

Etiology of Elevated Serum Creatinine in Patients with Systemic Lupus Erythematosus at Presentation and Association of Crescents in Renal Biopsy with Rapidly Progressive Renal Failure in a Lupus Cohort
Abstract Number: 1268

Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program
Abstract Number: 1289

Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery
Abstract Number: 0186

Evaluating the Effectiveness & Impact of an In-Person Peer Support Group That Transitioned to a Virtual Platform During the COVID-19 Pandemic
Abstract Number: L17

Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Abstract Number: 1645

Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis
Abstract Number: 1568

Evaluation for Allogeneic Hematopoietic Stem Cell Transplant Indications and Eligibility in a Prospective Cohort of Patients with VEXAS
Abstract Number: 1799

Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists
Abstract Number: 2135

Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
Abstract Number: 0124

Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Abstract Number: 1910

Evaluation of Dynamic Effects of Depressive Symptoms on Functional Outcomes in Knee Osteoarthritis
Abstract Number: 1182

Evaluation of Efficacy, Immunogenicity, and Toxicity of a Novel Drug Candidate for Scleroderma-associated Interstitial Lung Disease
Abstract Number: 2157

Evaluation of Functional Disability over Time in the Leiden Systemic Sclerosis (CCISS) Cohort
Abstract Number: 0942

Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls
Abstract Number: 0253

Evaluation of Patients with Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic
Abstract Number: 1309

Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid
Abstract Number: 2090

Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)
Abstract Number: 0452

Evaluation of the 2022 ACR/EULAR Classification Criteria for ANCA-Associated Vasculitis in a Population-based Cohort from Sweden
Abstract Number: 2175

Evaluation of the Distribution of Haemodynamic Parameters and Prognostic Impact in a Cohort of Patients with Systemic Sclerosis
Abstract Number: 0694

Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis
Abstract Number: 0540

Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE
Abstract Number: 0290

Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
Abstract Number: 2270

Evidence for Mitochondrial Dysfunction in Blood-derived Endothelial Colony Forming Cells Isolated from Patients with Antiphospholipid Syndrome
Abstract Number: 2058

Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Abstract Number: 1459

Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling
Abstract Number: 0809

Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira and AVT02
Abstract Number: 0521

Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis
Abstract Number: 1123

Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease
Abstract Number: PP11

Exercise as a Supportive Treatment for My Ankylosing Spondylitis
Abstract Number: 0846

Exercise Identity at the Start of Outpatient Physical Therapy Prospectively Predicts Physical Activity at 12-weeks After Total Knee Replacement
Abstract Number: 0337

Expanded Autoantibody Profiling in Incomplete Lupus Erythematosus
Abstract Number: 1164

Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience
Abstract Number: 0599

Expansion of HLA-DR+CD45RAhi Non-lymphoid Cells in Patients with Rheumatoid Arthritis
Abstract Number: 0776

Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
Abstract Number: 0275

Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials
Abstract Number: 1542

Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry
Abstract Number: 0933

Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
Abstract Number: 1334

Exploring Canadian Patient Experiences of Living with Lupus Nephritis (LN)
Abstract Number: 1783

Exploring How and Why Organizations Identify, Adopt, Disseminate, and Sustain Evidence-based Programs for Latinos with Arthritis
Abstract Number: 0184

Exploring Patient Journeys and Education Needs of Hispanic Individuals with Rheumatoid Arthritis
Abstract Number: 0963

Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy
Abstract Number: 1462

Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis
Abstract Number: 1707

Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE
Abstract Number: 0024

Exposure to Pollutants with Endocrine Disrupting Properties Is Associated with Early Cartilage Defects and Chondrocyte Inflammatory and Oxidative Activation
Abstract Number: 2140

Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast
Abstract Number: 0300

Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
Abstract Number: 0266

Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression
Abstract Number: 1265

External Validation of a Giant Cell Arteritis Probability Score (GCAPS) to Risk Stratify GCA Referrals: Experience from a United Kingdom Fast Track Clinic
Abstract Number: 0175

Extracorporeal Membrane Oxygenation for Acute Lung Injury in Idiopathic Inflammatory Myopathies – a Potential Lifesaving Intervention
Abstract Number: 1657

Extreme Phenotype Approach Identifies Rare Variants in Systemic Sclerosis and Dermatomyositis Patients with Severe Calcinosis
Abstract Number: 1715

Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice